Golden
IRX Therapeutics

IRX Therapeutics

A company developing immune therapies for cancer and related diseases

IRX Therapeutics is a clinical-stage bio-pharmaceutical company developing immunotherapies focused on reducing the immune suppression that is seen in the cancer tumor microenvironment, restoring immune function, and activating a coordinated immune response against the tumor.

The company's lead product candidate, IRX-2, is a proprietary therapeutic containing numerous active cytokine components. Studies indicate that IRX-2 acts to restore and activate multiple immune cell types, including T cells, dendritic cells, and natural killer cells to recognize and destroy tumors. It is a primary cell-derived biologic produced by stimulation of human peripheral blood mononuclear cells (PBMCs) obtained from healthy donor whole blood.

IRX-2 is being studied in an ongoing Phase 2B clinical trial in patients with newly diagnosed stage II, III, and IV squamous cell carcinoma of the head and neck and in preoperative early stage breast cancer.

In November 2018, IRX Therapeutics was acquired by Brooklyn ImmunoTherapeutics.

Timeline

People

Name
Role
Related Golden topics

Alex Efron

Employee

David Allen

Investor

James Egan

VP of Business Development

John Heilshorn

Investor

Joseph Swiader

Investor

Mark Leuchtenberger

President & CEO

Mark Lodish

Investor

Monil Shah

COO

Reza Movahedin

Employee

Further reading

Title
Author
Link
Type

IRX Therapeutics and ImmunID Announce Collaboration to Predict Response to IRX-2 Cancer Immunotherapy Using ImmunTraCkeR®

ImmunID & IRX Therapeutics

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

References